Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Mitigating the Spread of Hospital-Acquired Infections

During the global spread of the novel coronavirus, the ensuing COVID-19 pandemic and, now, efforts to engage in reopening, much has been said about strategies aimed at helping control infection in our daily lives. However, what about in the very facilities treating not only patients with COVID-19, but those with other conditions? Hospital-acquired infections, those…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

During the global spread of the novel coronavirus, the ensuing COVID-19 pandemic and, now, efforts to engage in reopening, much has been said about strategies aimed at helping control infection in our daily lives.

However, what about in the very facilities treating not only patients with COVID-19, but those with other conditions?

Hospital-acquired infections, those acquired in the hospital or place of treatment as opposed to prior to arriving at those facilities, can throw a major wrench in practices’ and hospitals’ ability to effectively care for patients.

Vioguard Vice President of Sales and Marketing, Mark Beeston, joined host Daniel Litwin to outline the company’s mission – improving infection control and helping curtail hospital-acquired infections – and how it goes about achieving those goals.

“[COVID-19] heightened awareness in the healthcare space,” Beeston said. “There were processes in place, already, but those processes have now been enhanced. You’re seeing more diligence in areas that are really hypersensitive.”

This heightened diligence has particularly affected places like newborn ICUs and operating rooms, and even families of patients are being more thoroughly screened and sanitized. It’s also increased attention on aspects of exposure that might have previously been overlooked, such as visitor cellphones.

Established in 2008, Vioguard develops solutions that utilize ultraviolet light to aid in sanitization efforts, working to provide effective infection control measures that don’t interfere with productivity or accuracy.

Litwin and Beeston explored how and why healthcare professionals might spread infection, the current state of prevention, and immediate and long-term strategies for avoiding hospital-acquired infections.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512